FDA approves two devices for treatment of OAB

The FDA has granted approval to two devices indicated for the treatment of overactive bladder.

The FDA has granted approval to two devices indicated for the treatment of overactive bladder.

Uroplasty, Inc.’s Urgent PC Neuromodulation System is a non-surgical nerve stimulation device designed for office-based treatment of overactive bladder symptoms. The minimally invasive device uses targeted neurostimulation to disrupt the signals that trigger urinary urgency and frequency.

Medtronic Inc.’s InterStim II system has gained FDA approval for the treatment of intractable cases of overactive bladder and urinary retention. The InterStim II adds a new implantable neurostimulator, improved patient programmer, and upgraded software for the clinician programmer. It is a smaller, lighter version of the original InterStim device, which received FDA approval in 1997.

Related Videos
blur image background of corridor in hospital or clinic image | Image credit: © whyframeshot - stock.adobe.com
Dr. David Canes in an interview with Urology Times
Urinary bladder | Image credit: © magicmine - stock.adobe.com
Blurred interior of hospital | Image credit: © jakkapan - stock.adobe.com
Blurry hospital corridor | Image credit: © zephyr_p - stock.adobe.com
Ricardo M. de Oliveira Soares, MD, answers a question during a Zoom video interview
Rachel Pope, MD, MPH, answers a question during a Zoom video interview
Raevti Bole, MD, answers a question during a Zoom video interview
© 2023 MJH Life Sciences

All rights reserved.